Clinical Trial Update: A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy study of AGN-19920 in patients with persistent erythema associated with rosacea has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythema
• Rosacea

Drugs mentioned

• AGN-19920

Snippet

Sponsor: Allergan | Conditions: Erythema, Rosacea | Phase 3 | Status: COMPLETED | Results posted: 2016-09-21